what glp 1 is serena williams taking discusses GLP-1 use as a Ro celebrity ambassador SERENA WILLIAMS JOINS RO AS

This gives adherence tools a clearer role between clinical visits

Corinne Rao is a board-certified internal medicine physician and founder of Legacy Physicians, specializing in functional medicine approaches to weight loss, hormonal health, stress and chronic disease management

Theoretically, increasing GLP-1 before a meal may decrease appetite and the amount eaten

These drugs work by mimicking the action of the hormone GLP-1, which stimulates insulin secretion, suppresses glucagon secretion, and slows gastric (stomach and intestine) emptying

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese